Diverticulitis and GLP-1 Drugs: Risk, Evidence and What Actually Matters

Diverticulitis is one of the more common reasons adults end up in an emergency department with abdominal pain, and carrying excess weight is one of its established risk factors ^{[1] [2]}. That makes it a reasonable thing to ask about when starting a GLP-1. There are two separate questions and they have different answers. Does losing weight reduce diverticulitis risk? The observational evidence points that way ^{[1] [3]}. Do GLP-1 drugs themselves cause diverticulitis? There is no evidence that they do — though their effect on the gut deserves a clear-eyed look ^{[5] [6]}.

The honest summary

• Excess weight raises diverticulitis risk, in both sexes. Women with a BMI of 35 or more had a hazard ratio of 1.42 versus women under 22.5 ^[1]. In men, a BMI of 30 or more carried a relative risk of 1.78 for diverticulitis and 3.19 for diverticular bleeding ^[2].
• Waist size matters independently of BMI. In men, the top fifth of waist circumference carried a relative risk of 1.56 for diverticulitis and 1.96 for diverticular bleeding ^[2].
• Lifestyle change lowers risk across genetic risk levels. Across 179,564 participants, a healthy lifestyle score of 5 versus 0 halved diverticulitis risk, with a hazard ratio of 0.50, and the benefit held whether genetic risk was low, middle or high ^[3].
• No evidence links GLP-1 drugs to diverticulitis. The GI safety literature on these drugs focuses on nausea, vomiting, constipation and rare obstruction — not diverticular disease ^{[5] [6]}.
• Constipation is the plausible indirect concern. It is a common GLP-1 side effect and is worth managing on its own terms, particularly if you already have diverticulosis.

What raises the risk, with numbers

The two strongest cohort studies come from the same research group and cover both sexes. In 46,079 women in the Nurses' Health Study, followed for six years with 1,084 incident cases, a BMI of 35 or above carried a hazard ratio for diverticulitis of 1.42 (95% CI 1.08 to 1.85) against a BMI under 22.5. The top fifth of waist circumference carried 1.35 and the top fifth of waist-to-hip ratio 1.40, both attenuating once BMI was accounted for ^[1].

In 47,228 men followed for eighteen years, with 801 cases of diverticulitis and 383 of diverticular bleeding, a BMI of 30 or more carried a relative risk of 1.78 for diverticulitis and 3.19 for diverticular bleeding, compared with a BMI under 21 ^[2]. The bleeding association is notably stronger than the inflammation one.

Does losing weight lower the risk?

No randomized trial has tested weight loss for diverticulitis prevention, so the honest answer is that the evidence is observational. What it shows is consistent. A 2025 analysis across three large cohorts — 179,564 people, validated in a separate community cohort and a biobank — built a healthy lifestyle score from smoking, BMI, physical activity, fiber and red meat intake. Moving from a score of 0 to 5 was associated with a hazard ratio of 0.50, and each one-point increase reduced risk similarly across low, middle and high genetic risk groups ^[3].

BMI is one of five components there, so this is not a clean weight-loss experiment. But it does answer a question people genuinely ask: if diverticulitis runs in your family, does lifestyle still matter? The data says yes, at every level of inherited risk ^[3].

What GLP-1 drugs do and do not do to the gut

These drugs have real gastrointestinal effects, and the literature is clear about what they are: nausea, vomiting, diarrhea and constipation are common, and rare cases of ileus and bowel obstruction have been reported ^[6]. A 2026 analysis of obstruction safety across agents and doses found the signal to be agent and dose specific rather than a uniform class effect ^[6]. Diverticulitis is not among the recognized effects.

The most directly reassuring data comes from a population with an already-irritable gut. In 271 adults with inflammatory bowel disease starting a GLP-1, rates of ileus or bowel obstruction, bowel surgery, disease-related hospitalization and escalation of therapy showed no significant difference between the year before and the year after starting treatment ^[5]. That is not a diverticulitis study, but it is the closest evidence that these drugs do not inflame a susceptible colon.

The constipation angle

The plausible indirect link runs through constipation, which is a common GLP-1 side effect. Harder stool and more straining are not good for a colon with diverticula. This is worth managing actively rather than tolerating: adequate fluid, gradual fiber, and movement. The current American Gastroenterological Association guideline on acute diverticulitis also reflects how much the field has moved — it recommends against routine antibiotics for uncomplicated cases and advises reassessing the old blanket advice to avoid nuts and seeds ^[4].

Practical guidance

• Diverticulosis alone is not a reason to avoid a GLP-1. Pouches are common and usually silent.
• Tell your prescriber if you have had diverticulitis before, especially more than once or with complications.
• Treat constipation early. It is the most plausible indirect risk and the easiest thing to fix.
• Build fiber back gradually as appetite returns. Fiber intake is one of the five components in the lifestyle score associated with halved risk ^[3].
• Know the red flags. Severe or persistent left-lower abdominal pain with fever is not a GLP-1 side effect and needs assessment.
• Do not stop a GLP-1 during an attack without advice, but do tell the treating clinician you take one, as it affects stomach emptying if a procedure is needed.